Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma: a Single-arm, Open-label Clinical Study

NCT05320081 is registered in ClinicalTrials.gov with Huazhong University of Science and Technology as lead sponsor.

NCT NCT05320081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05320081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma: a Single-arm, Open-label Clinical Study
Lead sponsor
Huazhong University of Science and Technology
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2021
Completion date
June 30, 2024
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, relapse/recurrence